Glaucoma
Drug research and approvals for glaucoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 186 studies of glaucoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, FDA has 1 approved and 5 open orphan designations naming it, and the EU has 11 authorised medicines for it.
- Recruiting worldwide: 186
- Trials authorized in Canada: 18
- FDA orphan approvals: 1
- EU medicines: 11
Recruiting now
Newest start dates first, of 186 recruiting on ClinicalTrials.gov ↗- Effect of Late Ripcord Removal From Glaucoma Drainage DeviceNCT07803536 · Not applicable · Duke University · starts Dec 1, 2026
- Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision ImpairmentNCT07341763 · Not applicable · University of Waterloo · starts Nov 1, 2026
- A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye…NCT07913074 · Phase 2 · Tavo Biotherapeutics · starts Oct 23, 2026
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamageNCT07770685 · Phase 1 / Phase 2 · Astellas Pharma Global Development, Inc. · starts Oct 7, 2026
- Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma PatientsNCT07847073 · Phase 4 · Brett King · starts Oct 1, 2026
- Efficacy and Safety of a Releasable Intraluminal Suture Technique to Reduce Hypotony Following Glaucoma Surgery Using…NCT07531199 · Not applicable · Hôpital Privé de la Baie · starts Sep 17, 2026
- REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07675824 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Sep 8, 2026
- Magnetic Resonance Imaging of Cerebral Connectivity and Volume in Neurodegeneration and GlaucomaNCT07802769 · Not applicable · University Hospital, Bordeaux · starts Aug 28, 2026
- A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and DiseasesNCT07780890 · Not reported · Massachusetts General Hospital · starts Aug 18, 2026
- Effects of Balance Training in Individuals With GlaucomaNCT07910955 · Not applicable · Kanuni Sultan Suleyman Training and Research Hospital · starts Aug 5, 2026
Drug pipeline
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indicationsApproved 24 of 32
- TimololBeta-1 adrenergic receptor antagonist
- LatanoprostProstanoid FP receptor agonist
- TravoprostProstanoid FP receptor agonist
- BrinzolamideCarbonic anhydrase II inhibitor
- MitomycinDNA inhibitor
- DorzolamideCarbonic anhydrase II inhibitor
- BrimonidineAdrenergic receptor alpha-2 agonist
- BimatoprostProstanoid FP receptor agonist
- TafluprostProstanoid FP receptor agonist
- AcetazolamideCarbonic anhydrase I inhibitor
- MethazolamideCarbonic anhydrase VII inhibitor
- PilocarpineMuscarinic acetylcholine receptor M3 agonist
- BetaxololBeta-1 adrenergic receptor antagonist
- CarteololAdrenergic receptor beta antagonist
- ClonidineAdrenergic receptor alpha-2 agonist
- LisdexamfetamineDopamine transporter releasing agent
- MetipranololBeta-1 adrenergic receptor antagonist
- DichlorphenamideCarbonic anhydrase I inhibitor
- AcetylcholineMuscarinic acetylcholine receptor M3 agonist
- CarbamoylcholineMuscarinic acetylcholine receptor M3 agonist
- DapiprazoleAlpha-1a adrenergic receptor antagonist
- LevobunololBeta-1 adrenergic receptor antagonist
- NeostigmineAcetylcholinesterase inhibitor
- IsoflurophateAcetylcholinesterase inhibitor
Phase 3 12 of 14
- BevacizumabVascular endothelial growth factor A inhibitor
- RanibizumabVascular endothelial growth factor A inhibitor
- AfliberceptVascular endothelial growth factor A inhibitor
- FluorouracilThymidylate synthase inhibitor
- Omidenepag isopropylProstanoid EP2 receptor agonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- OfloxacinBacterial DNA gyrase inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- LevobetaxololBeta-1 adrenergic receptor antagonist
- DexamethasoneGlucocorticoid receptor agonist
- Vitamin e
- NetarsudilRho-associated protein kinase inhibitor
Phase 2 11
- AMA0076Rho-associated protein kinase inhibitor
- Ciliary neurotrophic factor
- VerosudilRho-associated protein kinase inhibitor
- CyclosporineCyclophilin A modulator
- Triamcinolone acetonideGlucocorticoid receptor agonist
- PiclidenosonAdenosine A3 receptor agonist
- Cannabinol
- Zinpentraxin alfa
- OmidenepagProstanoid EP2 receptor agonist
- Befunolol
- Unoprostone
Phase 1 or earlier 12 of 13
- Insulin humanInsulin receptor agonist
- BosentanEndothelin receptor, ET-A/ET-B antagonist
- InfliximabTNF-alpha inhibitor
- Ethacrynic acidSodium-(potassium)-chloride cotransporter 2 inhibitor
- OmeprazolePotassium-transporting ATPase inhibitor
- CenegerminNeurotrophic tyrosine kinase receptor agonist
- Lutein
- Zeaxanthin
- Decorin
- RazuprotafibReceptor-type tyrosine-protein phosphatase beta inhibitor
- Bimatoprost grenod
- AcetaminophenCyclooxygenase inhibitor
How its trials ended
1,741 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 320 whose ending is known, 48% met their primary endpoint, 1% missed it and 51% stopped early.
- Completed, result not reported90652%
- Status unknown30217%
- Ongoing21312%
- Met its primary endpoint1539%
- Stopped: other or unclear945%
- Stopped: enrollment or feasibility352%
- Stopped: sponsor or business decision221%
- Stopped: lack of efficacy50%
- Missed its primary endpoint40%
- Stopped: funding40%
- Stopped: safety30%
Trials authorized in Canada
The 10 newest of 18; search them all in Canada trials| Jul 10, 2026 | Clinical trial protocol title: a phase 1/2 study of REGN22530 in participants with primary open angle glaucoma or ocular hypertensionREGN22530 | Regeneron | Ongoing |
| May 11, 2026 | A multicenter, compassionate adaptive clinical study evaluating the safety and performance of the migs silicone implant for intraocular pressure reduction in…Mitomycin | Hexiris Inc. | Pending |
| Mar 5, 2026 | A multicenter, first-in-human adaptive clinical study evaluating the safety and performance of the migs silicone implant for intraocular pressure reduction in…Mitomycin | Hexiris Inc. | Pending |
| Jan 29, 2026 | Prospective, multicenter study of the preserflo microshunt in subjects with primary open-angle glaucoma who have failed previous medical and surgical treatmentMitomycin | Glaukos | Ongoing |
| Nov 10, 2025 | A multicenter, first-in-human clinical study evaluating the safety and performance of the mist device for intraocular pressure reduction in patients with…Mitomycin | Hexiris Inc. | Ongoing |
| Dec 23, 2024 | Comparative efficacy of nsaid and steroid-nsaid combination following selective laser trabeculoplasty: a phase 3 single-centre randomized controlled trialKetorolac tromethamine/fluorometholone | The Research Insititute of St. Joseph's Hamilton | Pending |
| Dec 20, 2022 | Safety of insulin eye drops in the treatment of open-angle glaucomaHuman recombinant insulin | Santé Québec- Centre Hospitalier De L’université De Montréal | Pending |
| May 10, 2022 | Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus lumigan® 0.01% in ocular hypertensive or glaucomatous patientsBimatoprost (T4032) | Laboratoires Thea | Closed |
| Oct 21, 2019 | An investigator-initiated multi-center prospective clinical trial to examine the efficacy of peri-operative nsaid vs steroid treatment in trabeculectomy wound…Bromfenac | Lawson Health Research Institute | Pending |
| Mar 22, 2019 | An extension trial to evaluate the long-term safety and efficacy of bimatoprost sr in patients with open angle glaucoma or ocular hypertensionBimatoprost | AbbVie | Closed |
FDA orphan designations
Approved first, then open designations, newest first| Feb 7, 2012 | MitosolAn adjunct to ab externo glaucoma surgery. | Glaukos Corporation | Approved |
| Jun 4, 2015 | Synthetic 14-mer phosphorothioate antisense oligonucleotide…Prevention of scarring post glaucoma filtration surgery | Isarna Therapeutics GmbH | Designated |
| Mar 24, 2015 | 4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carbo…Prevention of scarring post ab externo glaucoma surgery | Clanotech AB | Designated |
| Dec 23, 2010 | TranilastPrevention of scarring following glaucoma filtration surgery | Esperante Development B.V. | Designated |
| Aug 20, 1993 | Mitomycin-CTreatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery. | IOP Inc. | Designated |
| Nov 16, 1987 | Thymoxamine HClReversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of… | Iolab Pharmaceuticals | Designated |
Medicines authorised in the EU
Newest first| Nov 15, 2023 | CatiolanzeLatanoprost | Santen Oy | EMA ↗ |
| Jan 7, 2021 | RoclandaLatanoprost / netarsudil | Santen Oy | EMA ↗ |
| Nov 19, 2019 | RhokiinsaNetarsudil | Santen Oy | EMA ↗ |
| Jul 18, 2014 | SimbrinzaBrinzolamide; brimonidine tartrate | Novartis Europharm Limited | EMA ↗ |
| Feb 20, 2014 | IzbaTravoprost | Novartis Europharm Limited | EMA ↗ |
| Nov 25, 2008 | AzargaBrinzolamide; timolol | Novartis Europharm Limited | EMA ↗ |
| May 19, 2006 | GanfortBimatoprost; timolol | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Apr 23, 2006 | DuoTravTravoprost; timolol | Novartis Europharm Limited | EMA ↗ |
| Mar 8, 2002 | LumiganBimatoprost | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Nov 27, 2001 | TravatanTravoprost | Novartis Europharm Limited | EMA ↗ |
| Mar 9, 2000 | AzoptBrinzolamide | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA